Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. - Wikidata - awgldk - TriplyDB

Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction.

Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction.

http://www.wikidata.org/entity/Q37277960

about

Incretin-Based Therapies for Diabetic Complications: Basic Mechanisms and Clinical Evidence The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies Recent advances in managing and understanding diabetic nephropathy Dipeptidyl peptidase-4 and kidney fibrosis in diabetes Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data?The clinical application of linagliptin in Asians Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes The Prevalence and Management of Diabetic Nephropathy in Asia Targeting inflammation in diabetes: Newer therapeutic options Present and future in the treatment of diabetic kidney disease Beat it early: putative renoprotective haemodynamic effects of oral hypoglycaemic agents Clinical therapeutic strategies for early stage of diabetic kidney disease.Safety and efficacy of the dipeptidyl peptidase-4 inhibitor linagliptin in elderly patients with type 2 diabetes: a comprehensive analysis of data from 1331 individuals aged ≥ 65 years.Tissue distribution of teneligliptin in rats and comparisons with data reported for other dipeptidyl peptidase-4 inhibitors.The effects of glucose-lowering therapies on diabetic kidney disease The use of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes & chronic kidney disease.How are patients with type 2 diabetes and renal disease monitored and managed? Insights from the observational OREDIA study Treatment of diabetic kidney disease: current and future targets.A randomized controlled trial comparing the effects of dapagliflozin and DPP-4 inhibitors on glucose variability and metabolic parameters in patients with type 2 diabetes mellitus on insulin.Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system Efficacy and safety of linagliptin in Hispanic/Latino patients with type 2 diabetes mellitus: a pooled analysis from six randomized placebo-controlled phase 3 trials The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system.Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment.Effects of a DPP4 inhibitor on cisplatin-induced acute kidney injury: study protocol for a randomized controlled trial.A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes.Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes.Potential for combination of dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors for the treatment of type 2 diabetes.Cardiovascular efficacy of sitagliptin in patients with diabetes at high risk of cardiovascular disease: a 12-month follow-up.Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers.Cardiovascular effects of dipeptidyl peptidase-4 inhibitors.An updated systematic review and meta-analysis on the efficacy and tolerability of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes with moderate to severe chronic kidney disease.Effects and Safety of Linagliptin as an Add-on Therapy in Advanced-Stage Diabetic Nephropathy Patients Taking Renin-Angiotensin-Aldosterone System Blockers.New therapeutic agents in diabetic nephropathy.Primary Care-Based Investigation of the Effect of Sitagliptin on Blood Pressure in Hypertensive Patients With Type 2 Diabetes.The gut-renal axis: do incretin-based agents confer renoprotection in diabetes?Dipeptidyl peptidase-4 inhibitors: pharmacokinetics, efficacy, tolerability and safety in renal impairment.Therapeutic approaches to diabetic nephropathy--beyond the RAS.Linagliptin: from bench to bedside.Understanding the type 2 diabetes mellitus and cardiovascular disease risk paradox.Linagliptin: an update of its use in patients with type 2 diabetes mellitus.

P2860

Q26739999-3AF1BA6B-6985-473E-B80F-994929A227EE Q26744317-AADAD2F4-FC1C-44BB-9C1D-CBC5D2F4D9A3 Q26745900-9BF0CC52-994A-4731-915F-1FD98EB7D018 Q26766089-B7666973-DE87-4333-B8AA-B34BEBDC8B6B Q26777994-8B239D37-DA0A-4437-AA9C-DDF37992C5C6 Q26781942-AC014343-72AA-4557-B3F9-0FD3DD7D61F1 Q26785454-982CEE07-67EB-4B31-B445-9472B8A9C6DA Q26851262-24AD0F4B-BB70-4AF7-981A-B702378CC022 Q26852726-2421BA99-8DE9-40B1-930A-FEFCBBDFB85F Q26864133-B36C0D7D-004B-49C2-9B20-E59C14FDF6FA Q27010669-84367D0E-8676-43FA-BBAB-B2CD3C21C34A Q30363683-AE14C61B-0463-45C2-A9B9-FF76C46BBEEE Q30827022-0CEC9A70-3908-44FB-A4EA-ABAD14F4CD6D Q31036099-B4A17BD0-960D-418D-9D99-E67D5676C12E Q33583220-C6BFCBA7-C82B-4430-85CD-C4341C41F41C Q33698333-DCF6C9B0-55B2-495B-9B92-4667171A759D Q33779315-40E2E5F7-4CD7-4633-A79B-ECC600552C1F Q33907249-D6834190-3E68-4979-ADDE-EE89ECE7782F Q33913060-0BB53BFB-A5D6-472A-8DA5-1F7781B85BFD Q34062829-F186DEF1-35EA-4758-A619-DBA2AD3FB151 Q34419202-BDC13BB2-BF11-4BBB-B474-50E210A9092A Q34503796-22F2CBE2-351A-4B1F-9D47-2899AC5090FD Q34891146-3F5960B3-A8F4-4DB6-8F4A-0D875168C73B Q35666901-7A704390-7A33-4C8E-B2FD-9831EA3F3425 Q36256469-C06871F8-AEFA-4D34-90B2-458B96B2F256 Q36302662-C7A5981D-1FAB-43D2-9B80-52FBA5296E6D Q36354599-CA00EC1D-2E41-4F0E-B279-1C6351BAA7A7 Q36758314-66344754-5368-40B7-8C6B-3617D45F6174 Q36851156-CC05004A-E16B-4124-9883-856A3196B80B Q37079289-ECD6D2F1-197F-4BED-A751-9FAA41DB8547 Q37141607-767B22CF-7111-4BA4-8624-CCD441F3453D Q37248403-B9AC851D-ED4D-4D28-A463-685E73A86497 Q37559164-C276EC1F-CCF9-4486-AEAE-9F92F7F383D7 Q37621225-7D6F0093-0C91-46CA-8FAA-DF463578A304 Q38174491-AEB36A57-A97B-4DBB-AABF-F284F61179FB Q38200670-F86EDECD-B9EF-4597-A804-546D7494E518 Q38209811-36A9617C-CCEC-4C71-84AF-C7F366A5E61C Q38213703-CEFB6DD0-5F3E-49DD-92FB-C1E6B14F010E Q38219490-D3DFACAE-32F7-4DA2-8ACC-8B553E127AA6 Q38258278-C3EB8C22-AD2C-4AEF-B7EB-971A391C4128

P2860

Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction.

http://www.wikidata.org/entity/Q37277960

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 11 September 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Linagliptin lowers albuminuria ...... iabetes and renal dysfunction.

@en

Linagliptin lowers albuminuria ...... iabetes and renal dysfunction.

@nl

type

label

Linagliptin lowers albuminuria ...... iabetes and renal dysfunction.

@en

Linagliptin lowers albuminuria ...... iabetes and renal dysfunction.

@nl

prefLabel

Linagliptin lowers albuminuria ...... iabetes and renal dysfunction.

@en

Linagliptin lowers albuminuria ...... iabetes and renal dysfunction.

@nl

P1433

Q37277960-B1F9248D-D1A4-49AE-B932-A0DE8DC4AB2E

P1476

Q37277960-C53B3185-12E6-4A87-9683-ABC24C02A967

P2093

Q37277960-538F0DF4-7594-4E88-96E2-514DF4A8445A

Q37277960-84194D50-FDE5-4285-9896-054360BF9B86

Q37277960-A0082F16-F613-4452-BD57-A58C5028EEC2

Q37277960-A31E08F7-327B-4F10-B62A-70DF51A946A2

P2860

Q37277960-09BB648B-90EC-4608-B988-CB637A4A88CA

Q37277960-14AE140B-997B-45CC-A90A-A3BFDE5DA7EC

Q37277960-1B68CE07-5F41-449D-B440-E2210FA50A59

Q37277960-290D2B5B-AEBF-483A-B530-0FD31F752E9A

Q37277960-2E6C6285-71B5-46A6-9C4C-9F74305D2C53

Q37277960-3146049D-6301-4ACE-9BA5-BB8779908DD7

Q37277960-3480BACA-3F99-4498-AD62-B81DADA6F813

Q37277960-3F8C7F1B-DD6C-4B00-BC5A-D30E26B6A3AA

Q37277960-44CBDDE2-0BAF-454E-B73B-508F80C93F9E

Q37277960-48054BB0-64DF-4D70-AF75-B333E78A9E7D

P304

Q37277960-D2BB9685-0162-4A00-B167-79BE84459D1B

P31

Q37277960-59A784B6-04EA-4729-B120-425052027171

P356

Q37277960-5D6AC510-DCDA-47D4-A331-7EB19AEC8CA9

P407

Q37277960-FC292815-2F49-4516-8EEC-1EF0B0283A9C

P433

Q37277960-A2872592-D4AF-43C0-9B64-9AB395081DDE

P478

Q37277960-4C722A3B-E269-4B42-975C-E7AEBA2EA778

P50

Q37277960-4F19227B-0AB8-4D29-B863-0F6CAFA26340

Q37277960-872FE22E-FAC4-4BFF-A3A8-6BB02C2AEE2A

Q37277960-EF6053A7-99B4-48E6-A601-73494A767C42

P577

Q37277960-50AABB5F-33FB-491C-ABCE-01BBF4ABEA5A

P5875

Q37277960-1C6463C5-9246-43B7-95A4-D4A16776F553

P698

Q37277960-62DCD041-7FF2-4645-94ED-C6E321CC8749

P921

Q37277960-0F289274-4297-46D4-B9C5-EB8F053C2A9D

Q37277960-1041C364-1610-4736-9450-7DAC1AA4C16B

P932

Q37277960-87F9710C-C48C-41E9-8A3D-5814B19F8FB7

P356

P1433

P1476

Linagliptin lowers albuminuria ...... iabetes and renal dysfunction.

@en

P2093

Angela Emser

http://www.w3.org/2001/XMLSchema#string

Hans-Juergen Woerle

http://www.w3.org/2001/XMLSchema#string

Mark E Cooper

http://www.w3.org/2001/XMLSchema#string

Maximilian von Eynatten

http://www.w3.org/2001/XMLSchema#string

P2860

Standards of medical care in diabetes--2012

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification

Prevalence of chronic kidney disease in the United States

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study.

Renal and retinal effects of enalapril and losartan in type 1 diabetes

P304

3460-3468

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DC13-0323

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

36

http://www.w3.org/2001/XMLSchema#string

P50

Maximilian von Eynatten

Per-Henrik Groop

P577

2013-09-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

256501327

http://www.w3.org/2001/XMLSchema#string

P698

24026560

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

3816860

http://www.w3.org/2001/XMLSchema#string